• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Tazorac (tazarotene) gel and cream 0.05% and 0.1%

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Tazorac (tazarotene) gel and cream 0.05% and 0.1%

  • Profile

Profile

Contact Information

Contact: Almirall
Website: https://www.tazorachcp.com/

Currently Enrolling Trials

    Show More

    General Information

    Tazorac (tazarotene) is a retinoid

    Tazorac Gel, 0.05% and 0.1% is a retinoid indicated for the topical treatment of plaque psoriasis of up to 20% body surface area involvement.

    Tazorac Gel, 0.1% is indicated for the topical treatment of mild to moderate facial acne vulgaris

    Tazorac  Cream 0.05% and 0.1% is a retinoid indicated for the topical treatment of plaque psoriasis.

    Tazorac Cream 0.1% is indicated for the topical treatment of acne vulgaris. 

    Apply a thin layer of Tazorac Gel or cream only to the affected area once daily in the evening. If contact with eyes occurs, rinse thoroughly with water.

    Mechanism of Action

    Tazorac is a receptor-selective retinoid. The gel is thought to normalize epidermal differentiation, reducing the influx of inflammatory cells into the skin. Its topical delivery targets the skin where these processes occur. Synthetic retinoids are vitamin A analogs and are thought to play a role in skin cell differentiation and proliferation.

    Side Effects

    Adverse effects associated with the use of Tazorac may include, but are not limited to, the following:

    Plaque Psoriasis:

    • pruritus
    • burning/stinging
    • erythema
    • worsening of psoriasis
    • irritation
    • skin pain

    Acne Vulgaris:

    • desquamation
    • burning/stinging
    • dry skin
    • erythema
    • pruritus

    Clinical Trial Results

    Tazorac showed treatment success in up to 70% of patients with stable plaque psoriasis when the gel was applied topically once a day. Tazorac gel showed rapid clinical improvement in plaque psoriasis and sustained a therapeutic effect for up to 12 weeks after treatment. Results from more than 1,400 patients found that up to 70% of patients with trunk limb plaque psoriasis and 60% with knee/elbow plaque psoriasis experienced treatment success, which was defined as good, excellent, or complete clearing of psoriasis. For treatment of common acne, the 0.1% gel demonstrated good to excellent efficacy in up to 70% of patients.

    Approval Date: 1997-06-01
    Company Name: Almirall
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Revamp-360x240.png

      Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

    • AskTheExpertsGreen-360x240.png

      Ask the Experts: Managing Investigational Products

    • SurveywBlueBackground-360x240.png

      Survey Outlines Site Challenges, Successes on Diversity

    • PatientCentricity-360x240.png

      Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing